전장 유전체 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 유형별, 워크플로우별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Whole Genome Sequencing Market Growth & Trends:

The global whole genome sequencing market size is projected to reach USD 6.67 billion by 2030, expanding at a CAGR of 22.17% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth can be attributed to the rising adoption of whole genome sequencing for genome mapping programs and the increasing prevalence of inherited disorders, including rare genetic disorders. According to the study published in the New England Journal of Medicine in November 2021, whole genome sequencing could lead to the early diagnosis of a wide range of rare diseases and a reported transition to precision medicine.

Furthermore, the growing investment in R&D for the early detection and treatment of disorders with the aid of WGS is expected to propel the growth of the market. For instance, in February 2023, the government of Indonesia and the Genome Science Initiative, with the aid of a USD 30 million investment from the Global Fund, established a network of facilities to perform the method for the early detection and treatment of disorders, including COVID-19, tuberculosis, cancer, genetic disorders, brain diseases, and metabolic disorders.

Whole genome sequencing has a wide range of applications, and government bodies are adopting these technologies for sequencing the genomes of humans, plant, animal, and microbes, which is expected to drive market growth. For instance, U.S. Food & Drug Administration (FDA) adopted the method to identify foodborne pathogens during foodborne disease outbreaks across the countries. The FDA has adopted this technology since 2008 under the Whole Genome Sequencing (WGS) program as it enables it to distinguish all strains of foodborne pathogens more efficiently than pulse-field gel electrophoresis (PFGE).

The rising technological advancements have led to the launch of innovative whole genome sequencing products that offer an affordable, accurate, and timely diagnosis of various diseases and infections. This is contributing to the growth of the market. For instance, in December 2022, LifeCell International Pvt. Ltd. collaborated with HaystackAnalytics to launch TB, a whole genome sequencing test to identify the diagnostic information on tuberculosis infections and tackle the drug resistance challenge.

The COVID-19 pandemic led to an increased demand for the method globally, which enabled the rapid identification of SARS-CoV-2 and the development of possible diagnostic tests to manage the outbreak. Hence, governments across the globe collaborated with research organizations and the corporate sector to use the method to identify and diagnose SARS-CoV-2. Several companies have launched genomic services and rapid solutions for the surveillance of the SARS-CoV-2 virus. For instance, QIAGEN offers the whole genome sequencing services SARS-CoV-2 surveillance for the identification of potent mutants, tracing of possible outbreaks, and advancement of vaccine research and drug development.

Whole Genome Sequencing Market Report Highlights:

• Consumables segment held the largest share of 61.56% in 2024, owing to the availability of a wide range of consumables and increased adoption of these products due to the shorter duration of use of these products
• By type, the large whole genome sequencing segment accounted for the largest share of 77.32% in the whole genome sequencing market in 2024. This can be attributed to the growing applications for analyzing cancerous tumors and identifying genetic variations in rare diseases
• By workflow, the sequencing segment held the largest market share of 52.12% in 2024, owing to the growing involvement of major companies and the launch of novel products to boost the adoption of the process
• By application, the human whole genome sequencing segment dominated the market in 2024 with a share of 62.91%. This can be attributed to the growing prevalence of rare inherited disorders and growing investment in R&D for the method to identify possible causative agents of these disorders
• By end-use, the academic & research institutes segment dominated the global market with the largest share of 48.72%. The large share of the segment can be attributed to the growing demand for high-throughput technologies at these facilities to conduct comprehensive research in this field
• North America held the largest market share of 51.34% in 2024. The large share can be attributed to the presence of a well-established healthcare system and pharmaceutical industry in the region, which has created a significant demand for whole genome sequencing for clinical and research purposes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product & Service Segment
  • 1.2.2. Type Segment
  • 1.2.3. Workflow Segment
  • 1.2.4. Application Segment
  • 1.2.5. End Use Segment
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Rising prevalence of inherited disorders
  • 3.2.2. Decreasing costs for genetic sequencing
  • 3.2.3. Rising demand for whole genome sequencing for genome mapping programs
• 3.3. Market Restraint Analysis
  • 3.3.1. Ethical and legal challenges associated with genomic sequencing
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Five Forces Analysis
  • 3.4.2. Macroeconomic Analysis
  • 3.4.3. COVID-19 Impact Analysis

Chapter 4. Whole Genome Sequencing Market: Product & Service Business Analysis

• 4.1. Product & Service Segment Dashboard
• 4.2. Global Whole Genome Sequencing Market: Product & Service Movement Analysis
• 4.3. Global Whole Genome Sequencing Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables Market, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Whole Genome Sequencing Market: Type Business Analysis

• 5.1. Type Segment Dashboard
• 5.2. Global Whole Genome Sequencing Market: Type Movement Analysis
• 5.3. Global Whole Genome Sequencing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Large Whole Genome Sequencing
  • 5.4.1. Large Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 5.5. Small Whole Genome Sequencing
  • 5.5.1. Small Whole Genome Sequencing Market, 2018 - 2030 (USD Million)

Chapter 6. Whole Genome Sequencing Market: Workflow Business Analysis

• 6.1. Workflow Segment Dashboard
• 6.2. Global Whole Genome Sequencing Market: Workflow Movement Analysis
• 6.3. Global Whole Genome Sequencing Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 6.4. Pre-Sequencing
  • 6.4.1. Pre-Sequencing Market, 2018 - 2030 (USD Million)
• 6.5. Sequencing
  • 6.5.1. Sequencing Market, 2018 - 2030 (USD Million)
• 6.6. Data Analysis
  • 6.6.1. Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 7. Whole Genome Sequencing Market: Application Business Analysis

• 7.1. Application Segment Dashboard
• 7.2. Global Whole Genome Sequencing Market: Application Movement Analysis
• 7.3. Global Whole Genome Sequencing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Human Whole Genome Sequencing
  • 7.4.1. Human Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 7.5. Plant Whole Exome Sequencing
  • 7.5.1. Plant Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 7.6. Animal Whole Exome Sequencing
  • 7.6.1. Animal Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 7.7. Microbial Whole Exome Sequencing
  • 7.7.1. Microbial Market, 2018 - 2030 (USD Million)

Chapter 8. Whole Genome Sequencing Market: End Use Business Analysis

• 8.1. End use Segment Dashboard
• 8.2. Global Whole Genome Sequencing Market: End use Movement Analysis
• 8.3. Global Whole Genome Sequencing Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 8.4. Academic & Research Institutes
  • 8.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 8.6. Pharmaceutical & Biotechnology Companies
  • 8.6.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Whole Genome Sequencing Market: Regional Business Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 9.3. North America
  • 9.3.1. North America Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. Reimbursement Scenario
    • 9.3.2.6. U.S. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. Canada Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. Mexico Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. Reimbursement Scenario
    • 9.4.2.6. Germany Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. UK Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. France Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. Italy Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. Spain Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Denmark Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Target Disease Prevalence
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Regulatory Framework
    • 9.4.8.5. Reimbursement Scenario
    • 9.4.8.6. Sweden Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Target Disease Prevalence
    • 9.4.9.3. Competitive Scenario
    • 9.4.9.4. Regulatory Framework
    • 9.4.9.5. Reimbursement Scenario
    • 9.4.9.6. Norway Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Reimbursement Scenario
    • 9.5.2.6. Japan Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. China Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Regulatory Framework
    • 9.5.4.5. Reimbursement Scenario
    • 9.5.4.6. India Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. Regulatory Framework
    • 9.5.5.5. Reimbursement Scenario
    • 9.5.5.6. South Korea Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Regulatory Framework
    • 9.5.6.5. Reimbursement Scenario
    • 9.5.6.6. Australia Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Competitive Scenario
    • 9.5.7.4. Regulatory Framework
    • 9.5.7.5. Reimbursement Scenario
    • 9.5.7.6. Thailand Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Reimbursement Scenario
    • 9.6.2.6. Brazil Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. Argentina Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Regulatory Framework
    • 9.7.2.5. Reimbursement Scenario
    • 9.7.2.6. South Africa Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. Regulatory Framework
    • 9.7.3.5. Reimbursement Scenario
    • 9.7.3.6. Saudi Arabia Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Target Disease Prevalence
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. Regulatory Framework
    • 9.7.4.5. Reimbursement Scenario
    • 9.7.4.6. UAE Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Target Disease Prevalence
    • 9.7.5.3. Competitive Scenario
    • 9.7.5.4. Regulatory Framework
    • 9.7.5.5. Reimbursement Scenario
    • 9.7.5.6. Kuwait Whole Genome Sequencing Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Position Analysis, 2024
• 10.4. Participant's Overview
  • 10.4.1. Illumina, Inc.
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.1.3. Product & Service Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Thermo Fisher Scientific, Inc.
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.2.3. Product & Service Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Oxford Nanopore Technologies
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.3.3. Product & Service Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Pacific Biosciences of California, Inc.
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.4.3. Product & Service Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. BGI
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.5.3. Product & Service Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. QIAGEN
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.6.3. Product & Service Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Agilent Technologies
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.7.3. Product & Service Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. ProPhase Labs, Inc. (Nebula Genomics)
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.8.3. Product & Service Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Psomagen
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.9.3. Product & Service Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Azenta US, Inc. (GENEWIZ)
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 10.4.10.3. Product & Service Benchmarking
    • 10.4.10.4. Strategic Initiatives